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Abstract 
Objectives To assess the knowledge of 
pharmacoeconomic (PE) information in patient groups, 
healthcare professionals, Government Formulary List 
Advisory Committee (GFLAC) and Pharmaceutical Research 
Based Industry Malta Association (PRIMA) members, to 
determine the extent to which PE information is used 
in formulary decision making and to define the specific 
challenges to adapt and establish the PE concept locally. 
 
Method A cross sectional study was conducted 
to investigate local PE knowledge and trend of use. A 
structured questionnaire was drafted. The questionnaire 
was distributed electronically to GFLAC members, health 
care professionals, patient groups and PRIMA members. 
A review of international PE guidelines was carried out 
followed by development of another questionnaire to 
obtain feedback from experienced Health Technology 
Assessment (HTA) and PE units in European countries. This 
questionnaire was disseminated to European organisations 
after obtaining permission to use 33 European countries 
listed on the International Society for Pharmacoeconomics 
Organisation (ISPOR) and the European Network for Health 
Technology Assessment (EUnetHTA) mail lists.
Key Findings Fourty out of a total of 74 electronically 
distributed questionnaires (response rate 54%) were 
returned. With regards to formulary decision making, the 
most influential profession was that of physicians whilst 
the most influential factors were drug efficacy and drug 
safety. The majority of participants are in favour of PE being 
required in formulary decision making. A total of 15 replies 
from 13 different European agencies were obtained. The 
majority of respondents agreed that Malta should adopt 
its own system of PE assessment. A further suggestion 
addressed the adaptation and tailoring of an existing 
national system and application of pharmacoeconomics in 
special cases.
Conclusion Results obtained in this study indicate 
that the concept of pharmacoeconomics should be required 
in formulary decision making and that Malta would benefit 
from adopting its own system of PE assessment.
KeyWords Pharmacoeconomics, Formulary Decision 
Making, Pharmacoeconomic Guidelines 
Introduction
Decision-makers at all levels of the health care system have 
been faced with increasing pressure to make more efficient 
use of existing health care resources.1 As a result, public 
and private agencies worldwide have turned to evidence-
based processes to improve assessment of the clinical 
and economic benefits of new and existing health care 
technologies. Although safety and efficacy are essential first 
considerations, Health Technology Assessments (HTAs) and 
economic evaluation, have become an integral component 
of the overall decision making process. An important subset 
of health economics is pharmacoeconomics which focuses 
solely on pharmaceuticals.2 This concept is applied to guide 
the use of limited resources to yield maximum value to 
patients, healthcare payers and society. 
Locally, availability of medicinal products within the 
Government Health Services is regulated by Legal Notice 
58 of 2009 of the Medicines Act. Although the Directorate 
for Pharmaceutical Affairs within the Ministry for Health 
processes HTAs, no governmental entity is responsible for 
PE assessments. The aims of this study were to assess the 
knowledge of PE information in patient groups, healthcare 
professionals, GFLAC and PRIMA members, to determine 
the extent to which PE information is used in formulary 
decision making and to define the specific challenges to 
adapt and establish the PE concept in Malta. 
Method 
A cross-sectional study was conducted to investigate local 
PE knowledge and trend of use. A structured questionnaire 
was drafted based on a 2010 study by Alsultan.3 The 
questionnaire was pre-tested for face and content validity by 
10 pharmacists experienced in the Government Formulary 
List. The questionnaire was distributed electronically to 
GFLAC and PRIMA members, health care professionals and 
patient groups. The questionnaire covered the following 
issues: influence of different professions in formulary 
decision making, potential use and helpfulness of PEs 
in the formulary decision making process, respondents’ 
understanding of PE data, and barriers in the use of PEs and 
future expectations in formulary decision making.
In the second part of the study a review of international 
PE guidelines was undertaken to determine the specific 
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Figure 1  Use of Pharmacoeconomic Data (N=40)
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Figure 2:  Pharmacoeconimics in Formulary Decision Making as other countries (N = 40)
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Rating 
challenges to adapt and establish the pharmacoeconomic 
concept. Eligibility criteria for inclusion required 
guidelines to be European, in the English language and 
published from 2003 onwards. The International Society 
of Pharmacoeconomics and Outcome Research (ISPOR) 
was contacted and the investigator (SMS) was invited to 
use the ISPOR HTA Road Maps and PE Guidelines tools4 
which were relevant for the study. Feedback was obtained 
from experienced PE units in European countries through 
another questionnaire. A questionnaire based on a previous 
Health Working Paper by the Organisation for Economic Co-
operation and Development  (OECD)5 was prepared. The 
draft questionnaire was pre-tested by 10 pharmacists for 
face and content validity. After obtaining permission from 
ISPOR and the European Network for Health Technology 
Assessment (EUnetHTA)6, the questionnaire was electronically 
disseminated to various European organisations. Topics 
included in the questionnaire were: the primary conceptual 
basis for the use of PE assessment, methods used for 
selecting new products and comparators for PE assessment, 
the accomplishments reached using PE, benefits of European 
co-operation for PE assessment and whether Malta would 
benefit from adopting its own system of PE assessment.
Results 
In the first part of the study, a total of 74 questionnaires 
were distributed; 40 responded with the majority being 
females (n=21), and the age range was between 41-55 
years. Most respondents were from the pharmaceutical 
profession (n=11). Formulary decision making, the most 
influential profession was found to be that of physicians 
(n=36) whilst drug efficacy (n=36) and drug safety 
(n=36) were the most influential factors. Out of these 40 
respondents, 21 used pharmacoeconomic data (Figure 1). 
Out of these 21 respondents who use PE data, 13 rated PE 
data as extremely helpful or very helpful, 12 used more 
than one type of PE data source and 11 rated themselves as 
somewhat knowledgeable in the understanding of PE data. 
Figure 2 indicates that the majority (n=37) of participants 
are in favour of PE being required in formulary decision 
making as in other countries. 
Figure 2: Pharmacoeconomics in Formulary Decision Making as in other countries (N = 40)
Figure 1: Use of Pharmacoeconomic Data (N=40)
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In the second part of the study, where the specific challenges 
to adapt and establish the PE concept were analysed, the 
ISPOR website has provided access to PE guidelines that 
are available internationally. Guidance documents are 
dated on the basis of publication and are categorised as: 
PE Recommendations, PE Guidelines, and Submission 
Guidelines.5 
A total of 15 replies from 13 different European agencies 
were obtained, the majority replying on an ‘own opinion’ 
basis (n=14). Four other agencies stated that they could not 
participate as they do not produce PE assessments (Table 1). 
The primary conceptual basis for the use of PE assessment 
is value for money for 8 agencies, Governmental entities are 
responsible for processing or conducting PE assessments in 
6 agencies and pharmaceutical companies are responsible 
for submitting the initial PE assessment for 11 agencies. All 
new products are eligble in the selection of pharmaceuticals 
for PE assessment for 8 agencies. Overall responding 
agencies positively agreed that PE assessments reduced 
total drug expenditure (n=11), reduced unnecessary drug 
use (n=9), improved prescribing cost effectiveness (n=8), 
and sensitised drug manufacturers to the need for effective 
drugs (n=8).
European Agency Country
Main Association of Austrian Social Security Institutions Austria
Health Research for Action Belgium
National Institute for Quality and Organisational Development 
in Healthcare and Medicines Hungary
National Centre for Pharmacoeconomics 
Ireland
Health Information and Quality Authority 
National Health Services Latvia
State Health Care Accreditation Agency Lithuania
Agency for Health Technology Assessment Poland
Health Technology Assessment (HTA) Consulting Poland
Scottish Medicines Consortium Scotland
Andalusian HTA Agency Spain
University Hospital of Geneva Switzerland
Dutch Health Care Insurance Board/Dutch Health Care  
Institute (now National Health Care Institute) The Netherlands
  
Table 1: Feedback from experience PE Units in Europe
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A positive attitude was observed towards European co-
operation and agreement since it strengthens the role 
of international agencies (n=12), may create mutually 
agreed guidelines (n=12), may create a standard format 
for companies to follow when submitting assessments 
(n=11), supports periodic discussion meetings to discuss 
assessment issues (n=11), facilitates communication among 
national assessment groups (n=12).
Figure 3 indicates that the majority (n=11) of respondents 
agree that Malta should adopt its own system of PE 
assessment. Other feedback and suggestions include to 
clarify the process and disseminate information on the 
chosen criteria to concerned clinicians, industry and policy 
makers, adapt and tailor an existing national system to be 
more efficient and to apply PE in special cases, as Malta 
is a small country with limited bargaining power over 
pharmaceutical companies.
Discussion
The overall local results are comparable and consistent 
with a study conducted by Alsultan3, altough in this study 
the target population included also representatives from 
patients and the pharmaceutical industry. When developing 
a PE approach to formulary development, the inclusion 
of experienced professionals, including pharmacists, 
who understand PE and who can analyse and convert 
data into useful information is considered to be critical.7 
In the early 1990s, Australia announced that economic 
analyses would be a submission requirement. Since then 
this policy has spread worldwide. Whilst feedback from 
European organisations was critical, overall results were still 
consistent with the 2003 OECD report4. Both the ISPOR and 
EUnetHTA were essential in providing a communication link 
with European organisations involved in PE assessments.
Pressure on healthcare budgets has increased so much 
that harmonisation requirements for HTA across Europe 
has become a political priority at EU level. The European 
Commission is contributing millions of euro to the 
EUnetHTA initiative; an HTA collaboration with EU member 
states, amongst them Malta. This is in line with EU Cross-
Border Healthcare Directive.8 
Conclusion
The trend appears to be that more jurisdictions, rather 
than fewer, are using economic analysis as part of their 
decision making procedures.9 Economic efficiency and 
maximising health outcomes for a given total budget is 
too often sacrificed in the pursuit of cost containment. The 
adoption of policies that take us beyond the drug budget 
silo mentality should be encouraged. The findings and 
feedback obtained from local and European respondents 
in this research is clearly in favour of the adaptation of the 
pharmacoeconomic concept in formulary decision making 
in Malta. Further research is required to identify the type of 
guidelines and methods which would be most suitable to 
the local scenario.
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